ALK and non-small cell lung carcinoma: Anaplastic lymphoma kinase (ALK) gene rearrangement was identified in NSCLC in 20071; the application of tyrosine kinase inhibitors (TKIs) targeting ALK fusion mutation developed rapidly and is proven to have good efficacy and safety in various clinical trials.